TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06668311

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: play dough
Description: 1. Children and families will be informed about the purpose of the study and their verbal and written consent will be obtained.~2. The first part of the Patient Information Form will be completed for children who accept the study.~3. The second part of the Patient Information Form will be completed five minutes before nebulizer treatment.~4. Five minutes before nebulizer treatment, play dough will be given to the child.~5. The child will be allowed to play with the play dough during the nebulizer treatment.~6. The second part of the Patient Information Form will be filled in at the 5th minute of the treatment and after the treatment is over.~7. The application will take approximately 15 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: picture book reading
Description: 1. Children and families will be informed about the purpose of the study and their verbal and written consent will be obtained.~2. The first part of the Patient Information Form will be completed for children who accept the study.~3. The second part of the Patient Information Form will be completed five minutes before nebulizer treatment.~4. Five minutes before nebulizer treatment, the child will be given a picture book.~5. Picture book will be read to the child during the treatment.~6. The second part of the Patient Information Form will be filled in at the 5th minute of the treatment and after the treatment is over.~7. The application will take approximately 15 minutes.
Study: NCT05016245

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: TheraSphere™ Yttrium-90 Glass Microspheres
Description: TheraSphere™ Yttrium-90 Glass Microspheres TheraSphere™ is steam sterilized and supplied in 6 standard dose sizes: 3 GBq, 5 GBq, 7 GBq, 10 GBq, 15 GBq, 20 GBq. Custom dose sizes are also available in 0.5 GBq increments between 3 and 20 GBq.~TheraSphereTM is supplied with the following accessories:~Administration Set Administration Accessory Kit

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional Transarterial Chemoembolization(cTACE)
Description: conventional Transarterial Chemoembolization(cTACE) is comprised of an anti-neoplastic agent(s) (i.e. cisplatin), lipiodol and embolic agent(s). The choice of agent(s) to be used is per usual local site practice. Chemotherapy agents can be as a single agent or used in combination, as per local practice.
Study: NCT05501860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-920
Description: AG-920 Sterile Topical Ophthalmic Solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Sterile Topical Ophthalmic Solution
Study: NCT06686654

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational hMPV/RSV vaccine
Description: Investigational hMPV/RSV vaccine administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational hMPV/RSV vaccine
Description: Investigational hMPV/RSV vaccine administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational hMPV/RSV vaccine
Description: Investigational hMPV/RSV vaccine administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational hMPV/RSV vaccine
Description: Investigational hMPV/RSV vaccine administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational hMPV/RSV vaccine
Description: Investigational hMPV/RSV vaccine administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational hMPV/RSV vaccine
Description: Investigational hMPV/RSV vaccine administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational hMPV/RSV vaccine
Description: Investigational hMPV/RSV vaccine administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational hMPV/RSV vaccine
Description: Investigational hMPV/RSV vaccine administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational hMPV/RSV vaccine
Description: Investigational hMPV/RSV vaccine administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational hMPV/RSV vaccine
Description: Investigational hMPV/RSV vaccine administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational hMPV/RSV vaccine
Description: Investigational hMPV/RSV vaccine administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational hMPV/RSV vaccine
Description: Investigational hMPV/RSV vaccine administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational hMPV/RSV vaccine
Description: Investigational hMPV/RSV vaccine administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational hMPV/RSV vaccine
Description: Investigational hMPV/RSV vaccine administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational hMPV vaccine (monovalent)
Description: Investigational hMPV vaccine (monovalent) administered intramuscularly
Study: NCT05048732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FluorApoTrace
Description: -The dose of 18F-FluorApoTrace to be given is 5 mCi

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FluorApoTrace
Description: -The dose of 18F-FluorApoTrace to be given is 5 mCi

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FluorApoTrace
Description: -The dose of 18F-FluorApoTrace to be given is 5 mCi
Study: NCT04674176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: 550 mg of Rifaximin 3 times a day for 12 days at the start of the diet.
Study: NCT06172010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clindamycin
Description: antimicrobial treatment in oral treatment phase of staphylococcal prosthetic joint infection
Study: NCT05484206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIR-2218
Description: VIR-2218 given by subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIR-2218
Description: VIR-2218 given by subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIR-3434
Description: VIR-3434 given by subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIR-3434
Description: VIR-3434 given by subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIR-3434
Description: VIR-3434 given by subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIR-3434
Description: VIR-3434 given by subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIR-3434
Description: VIR-3434 given by subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIR-3434
Description: VIR-3434 given by subcutaneous injection.
Study: NCT06172010

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampicin and levofloxacin
Description: antimicrobial treatment in oral treatment phase of staphylococcal prosthetic joint infection
Study: NCT04979130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Semaglutide 1.34 mg/mL solution for injection in 1.5 mL pre-filled PDS290 pen-injector provided by Novo Nordisk.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Semaglutide placebo, solution for injection, 1.5 mL pre-filled PDS290 pen-injector provided by Novo Nordisk.
Study: NCT05272098

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group A will receive myofascial release therapy + conventional physical therapy
Description: myofascial release therapy (4 sessions per week). It soft, deep and non-manipulative form of treatment that involves the application of gentle pressure while stretching the body's connective tissue. A specialized form of touch, somatic sense, and specific body movement protocols are the three steps involved in the myofascial release therapy + hot pack (15min) + back care advice and postural modification. A total of 45 min session four times a week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group B will receive endurance training of the trunk extensor muscles + conventional physical therapy
Description: It will be treated with endurance training of trunk extensor muscles. Erector spinae and latissimus dorsi will be included. The exercise protocol will be in four levels Bilateral shoulder left in prone position+ contralateral arm and leg lift in prone position+ both hands behind head and bilateral shoulder lift +bilateral shoulder lift with arm fully elevated + Hot pack (10 min) + back care advice and postural modification. A total of 45 min sessions four times a week.
Study: NCT01249105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2206
Description: Taken orally once a week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2206
Description: Taken orally once a week
Study: NCT05967312

Intervention type: DIAGNOSTIC_TEST
Intervention: Minuteful Kidney Test Kit
Description: The Minuteful Kidney Test is an Artificial Intelligence (AI) based innovative technology to enable people at risk of CKD to undertake an ACR test at home using smartphone technology
Study: NCT06686654

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational RSV vaccine (monovalent)
Description: Investigational RSV vaccine (monovalent) administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Licensed RSV Vaccine
Description: Licensed RSV vaccine administered intramuscularly

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered intramuscularly

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered intramuscularly

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered intramuscularly
Study: NCT04913363

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Green space
Description: Green space in which activities take place

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Green space
Description: Green space in which activities take place

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Green space
Description: Green space in which activities take place
Study: NCT06721013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirtobrutinib
Description: Administered orally
Study: NCT05413213

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ambulatory rehabilitation program
Description: Experimental group: Ambulatory rehabilitation program based on mobilization and muscular solicitation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ambulatory rehabilitation program
Description: Experimental group: Ambulatory rehabilitation program based on mobilization and muscular solicitation.
Study: NCT05307640

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CG-Well
Description: CG-Well is a web \& phone based psychosocial intervention that teaches caregivers how to obtain information, education \& support

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Information Support & Referral (ISR)
Description: Attention control group that receives phone calls and modules from the Brain Injury Association of America.
Study: NCT06176274

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prehabilition program
Description: this program includes nutrition, physical activity, medical optimization and psychological support interventions.As a practice, the prehabilitation program (according to the surgery program) is planned in the preoperative period between 2-4 weeks Dec. it will be applied for 4 weeks before surgery. the first meeting is scheduled for 40 minutes. the program compliance process will be monitored by phone weekly. postoperative recovery and functional capacity measurements will be performed.
Study: NCT06721013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirtobrutinib
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study: NCT06723743

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous vagus nerve stimulation for attention in veterans with TBI
Description: taVNS does not require surgery or medication, offering a safe and accessible treatment option. Each participant undergoes both an active taVNS session and a sham (placebo) session. Sham stimulation mimics the sensory experience of taVNS but does not deliver electrical currents to the vagus nerve, ensuring blinding and providing robust comparisons. The study is completed in a single visit lasting 2.5 to 3 hours, minimizing participant burden.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous vagus nerve stimulation for attention in veterans with TBI
Description: taVNS does not require surgery or medication, offering a safe and accessible treatment option. Each participant undergoes both an active taVNS session and a sham (placebo) session. Sham stimulation mimics the sensory experience of taVNS but does not deliver electrical currents to the vagus nerve, ensuring blinding and providing robust comparisons. The study is completed in a single visit lasting 2.5 to 3 hours, minimizing participant burden.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Soterix Medical Vagus Nerve Stimulation mini-CT
Description: Soterix Medical min-CT VNS device is used for non-invasive stimulation procedures and trials. It has blinding features such as single-blind for this study in which patients will either receive active or shame taVNS.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Soterix Medical Vagus Nerve Stimulation mini-CT
Description: Soterix Medical min-CT VNS device is used for non-invasive stimulation procedures and trials. It has blinding features such as single-blind for this study in which patients will either receive active or shame taVNS.
Study: NCT06740162

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PACE Program
Description: The PACE program is a 16-week inclusive exercise program taught and adapted by certified Inclusive Fitness Specialists. Study participants, called athletes, will engage in the fitness class with non-study participants with and without disabilities. Athlete participants will also meet weekly with their coaches (also study participants) to discuss goal setting and interact with the web-based dashboard.
Study: NCT06747962

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: A1 pulley release and pull out tenolysis
Description: A short transverse incision will be made over the proximal or distal palmar crease, according to the digit involved. Blunt dissection will be used to spread the subcutaneous tissue and the palmar fascia to expose the A1 pulley. The digital nerves and vessels will be retracted and protected. The proximal edge of the A1 pulley will be identified and a scalpel blade will be used to divide the entire A1 pulley under direct vision. Flexor digitorum superficialis and flexor digitorum profundus tendons or flexor pollicis longus tendon (for the thumb) will be gently pulled out of the wound with two mosquito forceps to break any adhesions. The wound will be closed primarily with sutures. The patient will be asked to actively move the digit to confirm complete relief of triggering.The wound will be closed primarily with sutures.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Simple A1 pulley release
Description: A short transverse incision will be made over the proximal or distal palmar crease, according to the digit involved. Blunt dissection will be used to spread the subcutaneous tissue and the palmar fascia to expose the A1 pulley. The digital nerves and vessels will be retracted and protected. The proximal edge of the A1 pulley will be identified and a scalpel blade will be used to divide the entire A1 pulley vision. After release, the patient will be asked to actively move the digit to confirm complete relief of triggering.The wound will be closed primarily with sutures.
Study: NCT06769620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORT247
Description: ORT247 will be provided to study sites in single-use, sterile vials for infusion. Each dose will be prepared with normal saline for infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo consists of normal saline
Study: NCT06757283

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Purified Vi capsular polysaccharide of Salmonella typhi conjugated to tetanus toxoid as carrier protein (Typhoid Vi Conjugate Vaccine I.P.). Trade name: ZyVac® TCV
Description: Purified Vi capsular polysaccharide of Salmonella typhi conjugated to tetanus toxoid as carrier protein (Typhoid Vi Conjugate Vaccine I.P.)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Purified Vi capsular polysaccharide of Salmonella typhi conjugated to tetanus toxoid as carrier protein (Typhoid Vi Conjugate Vaccine I.P.). Trade name: ZyVac® TCV
Description: Purified Vi capsular polysaccharide of Salmonella typhi conjugated to tetanus toxoid as carrier protein (Typhoid Vi Conjugate Vaccine I.P.)
Study: NCT06770673

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TOD Great Plains
Description: The adapted TOD intervention is rooted in the original TOD structure, delivery system, and home-visiting teaching schedule. Local enhancements include intervention topics and activities to address local adult caregivers' diabetes management and to promote families' modifiable risk and protective factors targeted by this proposal and informed by the Wicozani wellness concept and measurement. The TOD intervention includes targeted content taught approximately bi-weekly by family health coaches over a 16-week period.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Waitlist Standard of Care
Description: Participants who are waitlisted to receive the TOD intervention will receive Standard of Care.
Study: NCT06776978

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active treatment
Description: Participants receive anodic tDCS using a battery-driven Eldith (neuroConn GmbH) Programmable Direct Current Stimulator with surface-soaked sponge electrodes (5×7 cm). A constant current of 2 mA is applied for 20 minutes per session. The stimulation targets the left frontal region (F5 of the extended International 10-20 EEG system), corresponding to Broca's area, while the reference electrode is placed over the contralateral frontopolar cortex. tDCS is performed for 10 daily sessions over two consecutive weeks (5 days per week).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Stimulation
Description: Participants receive sham tDCS using a battery-driven Eldith (neuroConn GmbH) Programmable Direct Current Stimulator with surface-soaked sponge electrodes (5×7 cm). No therapeutic current is applied during the 20-minute session. The electrode placement mimics the active condition, targeting the left frontal region (F5 of the extended International 10-20 EEG system), corresponding to Broca's area, while the reference electrode is placed over the contralateral frontopolar cortex. Sham tDCS is performed for 10 daily sessions over two consecutive weeks (5 days per week).
Study: NCT06776913

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Colonoscopy after bowel cleansing
Description: Standard Colonoscopy with photo documentation and the recording of procedure timing.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Colonoscopy after bowel cleansing
Description: Standard Colonoscopy with photo documentation and the recording of procedure timing.
Study: NCT05938452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glyceryl Tribenzoate
Description: Oral Solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glyceryl Tribenzoate
Description: Oral Solution
Study: NCT06090747

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hybrid lifestyle educational multidisciplinary intervention.
Description: Participants will receive a standardized educational healthy lifestyle intervention. The information will be shared via digital tools such as mail, WhatsApp, zoom workshops, educational videos, Joven, Fuerte y Saludable webpage, Joven, Fuerte y Saludable mobile app, and face-to-face educational sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hybrid lifestyle personalized multidisciplinary intervention.
Description: Participants will receive a standardized educational healthy lifestyle intervention and personalized lifestyle intervention based on their clinical evaluation. Based on clinical records participants will be sent to nutritional, psychological, rehabilitation, and Mindfulness intervention. Educational and motivational strategies include digital tools such as mail, WhatsApp, zoom workshops, educational videos, the Joven, Fuerte y Saludable webpage, and the Joven, Fuerte y Saludable mobile app. And individualized follow-up through Mobile apps such as AVENA
Study: NCT05012137

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided Supra-anterior Superior Iliac Spine Fascia Iliaca Compartment Block (SASIS-FICB) with 0.5% ropivacaine
Description: all the patients received Ultrasound-guided Supra-anterior Superior Iliac Spine Fascia Iliaca Compartment Block (SASIS-FICB)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: different volume of 0.5% ropivacaine
Description: According to the subject's response to the injection dose, the next subject will be injected with a different volume of the drug according to the preset rules
Study: NCT05237700

Intervention type: OTHER
Intervention: Patient positioning on operating table
Description: The patients are either positioned in Trendelenburg with lithotomy positioning or in Trendelenburg without lithotomy positioning on the operating table when undergoing robotic assisted laparoscopic surgery or laparoscopic surgery.

Intervention type: OTHER
Intervention: Patient positioning on operating table
Description: The patients are either positioned in Trendelenburg with lithotomy positioning or in Trendelenburg without lithotomy positioning on the operating table when undergoing robotic assisted laparoscopic surgery or laparoscopic surgery.
Study: NCT05085054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib Mesylate
Description: Participants will receive targeted therapy followed by salvage surgery